The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients
Abstract Background Neoadjuvant chemotherapy is a key component of breast cancer treatment regimens and pathologic complete response to this therapy varies among patients. This is presumably due to differences in the molecular mechanisms that underlie each tumor’s disease pathology. Developing genom...
Main Authors: | Kenneth M. K. Mark, Frederick S. Varn, Matthew H. Ung, Feng Qian, Chao Cheng |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-05-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-017-3297-2 |
Similar Items
-
Non Parametric Unsupervised Clustering of ChIP Enrichment Regions Provides Isolation Vectors for Differential Functional Analysis
by: Griffith, Alexander
Published: (2016) -
ChIP-seq profiling of the active chromatin marker H3K4me3 and PPARγ, CEBPα and LXR target genes in human SGBS adipocytes
by: Mafalda Galhardo, et al.
Published: (2014-12-01) -
Survival outcomes of locally advanced gastric cancer cases with pathological complete response received neoadjuvant chemotherapy
by: Qing Hu, et al.
Published: (2021-06-01) -
Identification à l'échelle génomique de gènes transcrits par deux isoformes de l'ARN polymérase III humaine
by: Pascali, Chiara
Published: (2011) -
The implications of a pathological complete response of the primary tumour after neoadjuvant chemotherapy for breast cancer on axillary surgery
by: Mina M. G. Youssef, et al.
Published: (2021-02-01)